Review

suspension cell lines supt1 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC suspension cell lines supt1

Transduction of <t>SupT1</t> (A) and Jurkat (B) cells with wild-type (wt) and CD7-engineered AAVs of different serotypes (10,000 gc/cell). Shown are relative % GFP-positive cells at 3 dpi compared to corresponding wt AAV serotype (mean ± SD, n=3). Absolute percentage GFP-positive cells are indicated inside the bars. C ) Representative flow cytometry plots of activated human PBMCs transduced with indicated rAAVs (100,000 gc/cell). D) Absolute % GFP-positivity at 3 dpi (mean ± SD, n≥4). Individual values are presented as dots. E) CD7-specificity factor for transduction (10,000 gc/cell) of activated PBMCs at 3 dpi (mean ± SD, n=3). F) Transduction of activated human PBMCs with indicated rAAVs (100,000 gc/cell) and stratification of GFP-positive cells at 3 dpi in CD4 + T, CD8 + T and NK (CD56 + ) cell types (mean ± SD, n≥3; dot colors represent biologically independent human cell samples). G) Transduction of hepatocyte (HuH-7, HepG2) and kidney (HEK293T) cell lines with indicated rAAVs (100.000 gc/cell). Absolute % GFP-positive cells at 3 dpi (mean ± SD, n=3). rAAV Vectors contained the following sequences: AAV6 & AAV2 = self-complementary genome, CAG promoter; AAV9 & AAV6/9 = single stranded genome, SFFV promoter. Mean ± SD, n=3. For all panels statistical analysis utilized unpaired t-test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).

Suspension Cell Lines Supt1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 616 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/suspension+cell+lines+supt1/SUP-T1/bio_rxiv__64898__2026__02__26__707014-104-0-4
Average 97 stars, based on 616 article reviews

suspension cell lines supt1 - by Bioz Stars, 2026-10

97/100 stars

Images

1) Product Images from "Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy"

Article Title: Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy

Journal: bioRxiv

doi: 10.64898/2026.02.26.707014

Transduction of SupT1 (A) and Jurkat (B) cells with wild-type (wt) and CD7-engineered AAVs of different serotypes (10,000 gc/cell). Shown are relative % GFP-positive cells at 3 dpi compared to corresponding wt AAV serotype (mean ± SD, n=3). Absolute percentage GFP-positive cells are indicated inside the bars. C ) Representative flow cytometry plots of activated human PBMCs transduced with indicated rAAVs (100,000 gc/cell). D) Absolute % GFP-positivity at 3 dpi (mean ± SD, n≥4). Individual values are presented as dots. E) CD7-specificity factor for transduction (10,000 gc/cell) of activated PBMCs at 3 dpi (mean ± SD, n=3). F) Transduction of activated human PBMCs with indicated rAAVs (100,000 gc/cell) and stratification of GFP-positive cells at 3 dpi in CD4 + T, CD8 + T and NK (CD56 + ) cell types (mean ± SD, n≥3; dot colors represent biologically independent human cell samples). G) Transduction of hepatocyte (HuH-7, HepG2) and kidney (HEK293T) cell lines with indicated rAAVs (100.000 gc/cell). Absolute % GFP-positive cells at 3 dpi (mean ± SD, n=3). rAAV Vectors contained the following sequences: AAV6 & AAV2 = self-complementary genome, CAG promoter; AAV9 & AAV6/9 = single stranded genome, SFFV promoter. Mean ± SD, n=3. For all panels statistical analysis utilized unpaired t-test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).

Figure Legend Snippet: Transduction of SupT1 (A) and Jurkat (B) cells with wild-type (wt) and CD7-engineered AAVs of different serotypes (10,000 gc/cell). Shown are relative % GFP-positive cells at 3 dpi compared to corresponding wt AAV serotype (mean ± SD, n=3). Absolute percentage GFP-positive cells are indicated inside the bars. C ) Representative flow cytometry plots of activated human PBMCs transduced with indicated rAAVs (100,000 gc/cell). D) Absolute % GFP-positivity at 3 dpi (mean ± SD, n≥4). Individual values are presented as dots. E) CD7-specificity factor for transduction (10,000 gc/cell) of activated PBMCs at 3 dpi (mean ± SD, n=3). F) Transduction of activated human PBMCs with indicated rAAVs (100,000 gc/cell) and stratification of GFP-positive cells at 3 dpi in CD4 + T, CD8 + T and NK (CD56 + ) cell types (mean ± SD, n≥3; dot colors represent biologically independent human cell samples). G) Transduction of hepatocyte (HuH-7, HepG2) and kidney (HEK293T) cell lines with indicated rAAVs (100.000 gc/cell). Absolute % GFP-positive cells at 3 dpi (mean ± SD, n=3). rAAV Vectors contained the following sequences: AAV6 & AAV2 = self-complementary genome, CAG promoter; AAV9 & AAV6/9 = single stranded genome, SFFV promoter. Mean ± SD, n=3. For all panels statistical analysis utilized unpaired t-test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).

Techniques Used: Transduction, Flow Cytometry

Suspension:

Article Title: Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy
Article Snippet: Adherent HEK293T (ATCC: CRL-3216), HepG2 (ATCC: HB-8065) and HuH-7 (JCRB0403) [ ], cells were cultured in DMEM (Pan-Biotech) supplemented with 10% fetal calf serum (FCS; Pan Biotech), and 50 U/mL Penicillin and 50 μg/mL Streptomycin (Pan Biotech) and passaged using 0.05% trypsin-EDTA (Pan-Biotech). .. Suspension cell lines SupT1 (ATCC: CRL-1942) and Jurkat (RRID: CVCL_C831) were maintained in RPMI 1640 (Biozym Scientific) with 10% FCS, 50 U/mL Penicillin and 50 μg/mL Streptomycin (Pan Biotech). .. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy donors (University Hospital Hamburg-Eppendorf) and cultured in RPMI 1640 with 10% FCS, 50 U/mL Penicillin and 50 μg/mL Streptomycin (Pan Biotech), 200 U/mL recombinant human IL-2 (Sigma-Aldrich).

Image Search Results

Journal: bioRxiv

Article Title: Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy

doi: 10.64898/2026.02.26.707014

Figure Lengend Snippet: Transduction of SupT1 (A) and Jurkat (B) cells with wild-type (wt) and CD7-engineered AAVs of different serotypes (10,000 gc/cell). Shown are relative % GFP-positive cells at 3 dpi compared to corresponding wt AAV serotype (mean ± SD, n=3). Absolute percentage GFP-positive cells are indicated inside the bars. C ) Representative flow cytometry plots of activated human PBMCs transduced with indicated rAAVs (100,000 gc/cell). D) Absolute % GFP-positivity at 3 dpi (mean ± SD, n≥4). Individual values are presented as dots. E) CD7-specificity factor for transduction (10,000 gc/cell) of activated PBMCs at 3 dpi (mean ± SD, n=3). F) Transduction of activated human PBMCs with indicated rAAVs (100,000 gc/cell) and stratification of GFP-positive cells at 3 dpi in CD4 + T, CD8 + T and NK (CD56 + ) cell types (mean ± SD, n≥3; dot colors represent biologically independent human cell samples). G) Transduction of hepatocyte (HuH-7, HepG2) and kidney (HEK293T) cell lines with indicated rAAVs (100.000 gc/cell). Absolute % GFP-positive cells at 3 dpi (mean ± SD, n=3). rAAV Vectors contained the following sequences: AAV6 & AAV2 = self-complementary genome, CAG promoter; AAV9 & AAV6/9 = single stranded genome, SFFV promoter. Mean ± SD, n=3. For all panels statistical analysis utilized unpaired t-test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).

Article Snippet: Suspension cell lines SupT1 (ATCC: CRL-1942) and Jurkat (RRID: CVCL_C831) were maintained in RPMI 1640 (Biozym Scientific) with 10% FCS, 50 U/mL Penicillin and 50 μg/mL Streptomycin (Pan Biotech).

Techniques: Transduction, Flow Cytometry

(A) CD4 expression on cell lines used in this study. Cells were stained with anti-CD4-Cy7 antibody and compared to unstained mock controls. The CD4 signal in mock cells was manually adjusted to 100 arbitrary units and compared with stained cells by flow cytometry. Histograms were normalized by modal mode to visualize comparable peak heights. (B) Two HeLa (wt and TZMbl) and two T lymphoid (1G5 and SupT1) cell lines were transduced with the indicated viral vector genome copies per cell (gc/cell). Three days post infection the % of eGFP positive cells was determined by flow cytometry; n = 2–4. Error bars indicate the SD. (C) 1G5 cells were transduced with the indicated AAV2 particles at a concentration of 10,000 gc/cell. Three days post transduction cells were stained for CD4 expression and analyzed for GFP expression by flow cytometry. Representative data are shown.

Journal: PLoS ONE

Article Title: Improved targeting of human CD4 + T cells by nanobody-modified AAV2 gene therapy vectors

doi: 10.1371/journal.pone.0261269

Figure Lengend Snippet: (A) CD4 expression on cell lines used in this study. Cells were stained with anti-CD4-Cy7 antibody and compared to unstained mock controls. The CD4 signal in mock cells was manually adjusted to 100 arbitrary units and compared with stained cells by flow cytometry. Histograms were normalized by modal mode to visualize comparable peak heights. (B) Two HeLa (wt and TZMbl) and two T lymphoid (1G5 and SupT1) cell lines were transduced with the indicated viral vector genome copies per cell (gc/cell). Three days post infection the % of eGFP positive cells was determined by flow cytometry; n = 2–4. Error bars indicate the SD. (C) 1G5 cells were transduced with the indicated AAV2 particles at a concentration of 10,000 gc/cell. Three days post transduction cells were stained for CD4 expression and analyzed for GFP expression by flow cytometry. Representative data are shown.

Article Snippet: Suspension T cell lines SupT1 (ATCC: CRL-1942) and Jurkat 1G5 (NIBSC: 5010) were cultivated in RPMI 1640 growth medium (Biozyme Scientific) supplemented with 10% fetal calf serum (Pan-Biotec, Aidenbach, Germany) and 50 U/mL penicillin-streptomycin.

Techniques: Expressing, Staining, Flow Cytometry, Transduction, Plasmid Preparation, Infection, Concentration Assay